Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Relationship between lenalidomide dose modification, duration of therapy, and long-term outcomes in patients with myelodysplastic syndromes

    ... myelodysplastic syndromes (MDS) treated with lenalidomide ; such modifications are recommended to sustain therapy and ... case-control study was to determine the relationship between lenalidomide dose modification (DM), duration of lenalidomide therapy (DOT), ...

    Research Article last updated 11/08/2017 - 9:12am.

  2. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond

    ... disease subset that is exquisitely sensitive to lenalidomide for the treatment of red blood cell transfusion -dependent anemia . Although lenalidomide has erythropoeitic promoting activity in MDS without del(5q) ... to biologically separate drug effects. In del(5q) MDS, lenalidomide suppresses the malignant clone to restore effective ...

    Research Article last updated 10/23/2017 - 10:58am.

  3. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond

    ... disease subset that is exquisitely sensitive to lenalidomide for the treatment of red blood cell transfusion -dependent anemia . Although lenalidomide has erythropoeitic promoting activity in MDS without del(5q) ... to biologically separate drug effects. In del(5q) MDS, lenalidomide suppresses the malignant clone to restore effective ...

    Research Article last updated 10/02/2017 - 9:54am.

  4. Lenalidomide

    ... Lenalidomide is a capsule that is taken by mouth. It is approved for ... with a broader range of MDS patients. For some MDS patients, lenalidomide can improve anemia and reduce or eliminate the need for ...

    Drug last updated 03/24/2016 - 12:32pm.

  5. Shauna McMillan - Alaskan Goes Home for Treatment and a Fresh Start

    ... was also when my treatments began. I was placed on lenalidomide (Revlimid®) injections for 12 weeks at which point it was ...

    Patient Chronicle last updated 01/09/2018 - 2:24pm.

  6. Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy.

    ... While lenalidomide (LEN) is the standard of care for the lower-risk ... 5q deletion and to analyze their outcome after failure of lenalidomide. The median survival following LEN failure was 23 months. We ...

    Research Article last updated 07/11/2017 - 10:11am.

  7. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

    ... (MDS). Whether azacitidine-based combinations with lenalidomide or vorinostat produce superior overall response rates (ORRs) ... on days 1 to 7 of a 28-day cycle); azacitidine plus lenalidomide (10 mg/day on days 1 to 21); or azacitidine plus vorinostat (300 ...

    Research Article last updated 05/22/2017 - 10:52am.

  8. Pro-inflammatory proteins S100A9 and TNFα suppress erythropoietin elaboration in myelodysplastic syndromes

    ... and response to erythroid stimulating agents or lenalidomide has not been investigated. The HepG2 hepatoma cell line was ... (125 prior to erythroid stimulating agents and 186 prior to lenalidomide). Serum concentrations of S100A9, S100A8, TNFα, IL1β and Epo ...

    Research Article last updated 10/20/2017 - 9:16am.

  9. Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia

    ... of four cases receiving sequential clofarabine and lenalidomide for high risk MDS and AML in a phase I study. Our results ...

    Research Article last updated 05/22/2017 - 11:42am.

  10. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine

    ... BACKGROUND: Lenalidomide and azanucleosides are commonly used to treat anemic patients ... agents (ESAs). Nonetheless, response rates to lenalidomide after azanucleosides treatment failure and their optimal ... in the Moffitt Cancer Center Clinical Database who received lenalidomide and azacitidine after ESA treatment failure. Rates of ...

    Research Article last updated 12/09/2015 - 8:59am.